Brivekimig

DRUG3 trials

Sponsors

Sanofi

Conditions

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal LesionHidradenitis SuppurativaType 1 Diabetes Mellitus

Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

RecruitingNCT06500702

SanofiFocal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

Start: 2024-12-19End: 2028-02-16Target: 84Updated: 2026-03-20

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Active, not recruitingNCT06812988

SanofiType 1 Diabetes Mellitus

Start: 2025-02-28End: 2027-04-29Target: 84Updated: 2026-03-13

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

RecruitingNCT07170917

SanofiHidradenitis Suppurativa

Start: 2025-11-06End: 2028-04-27Target: 208Updated: 2026-03-11

Related Papers

#1802 Development of the Nephrotic Syndrome Symptom and Impact Patient Reported Outcome (NephroSSI-PRO) measure for use in adults and adolescents with primary glomerulopathies

Nephrology Dialysis Transplantation2025-10-01